ArticleThe Journal of infectious diseases2026
Genetic Background Modulates Zoliflodacin and Gepotidacin Cross-Resistance and Fitness in Neisseria gonorrhoeae.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- Put your money where your mouth is: surveillance of antibiotic resistance within the commensalMicrobiology spectrum · 2026Article
- Limitations of Global Surveillance for Neisseria gonorrhoeae Antimicrobial Resistance.Emerging infectious diseases · 2026Review
- The Influence of National Antibiotic Consumption on Neisseria Gonorrhoeae Antibiotic Resistance in Norway, 2003-2024.The Journal of infectious diseases · 2026Article
- Fluoroquinolone resistance-conferringbioRxiv : the preprint server for biology · 2026Article
- Put your money where your mouth is: Surveillance of antibiotic resistance within the commensalbioRxiv : the preprint server for biology · 2026Article
- Pre-clinical efficacy of a C4BP hexameric IgG Fc fusion protein against Neisseria gonorrhoeae.PloS one · 2026Article
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
backgroundThe emergence of multidrug-resistant Neisseria gonorrhoeae has created an urgent need for new therapeutic options. Zoliflodacin and gepotidacin, 2 first-in-class topoisomerase inhibitors, are oral antibiotics recently approved by the FDA for gonorrhea treatment. Resistance to zoliflodacin can occur through gyrBD429N, but this mutation's impact on fitness and on resistance to other topoisomerase-targeting drugs have been unclear. The aim of this study was to investigate the in vitro fitness and antibiotic resistance implications of gyrBD429N in ciprofloxacin-resistant N. gonorrhoeae strains.
methodsWe introduced the gyrBD429N substitution into 9 clinical strains via transformation. Antimicrobial susceptibility testing was performed for zoliflodacin, gepotidacin, and ciprofloxacin using standard MIC assays. In vitro relative fitness of parent and resistant mutant strains was assessed by pairwise competition experiments.
resultsgyrB D429N conferred cross-resistance to gepotidacin in 3 clinical strains, and its fitness effect varied by strain background. In particular, parCD86N appeared to potentiate gyrBD429N cross-resistance to gepotidacin, a drug for which resistance has previously only been seen in the presence of both parCD86N and gyrAA92T mutations.
conclusionsGenetic background modulated the phenotypic effects of a zoliflodacin-resistance determinant on fitness and cross-resistance to gepotidacin. These findings inform strategies for introducing the new topoisomerase inhibitors into clinical use and for surveillance of resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.